These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

262 related articles for article (PubMed ID: 27329448)

  • 1. Lipoprotein-Associated Phospholipase A2 Activity Is a Marker of Risk But Not a Useful Target for Treatment in Patients With Stable Coronary Heart Disease.
    Wallentin L; Held C; Armstrong PW; Cannon CP; Davies RY; Granger CB; Hagström E; Harrington RA; Hochman JS; Koenig W; Krug-Gourley S; Mohler ER; Siegbahn A; Tarka E; Steg PG; Stewart RA; Weiss R; Östlund O; White HD;
    J Am Heart Assoc; 2016 Jun; 5(6):. PubMed ID: 27329448
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Darapladib for preventing ischemic events in stable coronary heart disease.
    ; White HD; Held C; Stewart R; Tarka E; Brown R; Davies RY; Budaj A; Harrington RA; Steg PG; Ardissino D; Armstrong PW; Avezum A; Aylward PE; Bryce A; Chen H; Chen MF; Corbalan R; Dalby AJ; Danchin N; De Winter RJ; Denchev S; Diaz R; Elisaf M; Flather MD; Goudev AR; Granger CB; Grinfeld L; Hochman JS; Husted S; Kim HS; Koenig W; Linhart A; Lonn E; López-Sendón J; Manolis AJ; Mohler ER; Nicolau JC; Pais P; Parkhomenko A; Pedersen TR; Pella D; Ramos-Corrales MA; Ruda M; Sereg M; Siddique S; Sinnaeve P; Smith P; Sritara P; Swart HP; Sy RG; Teramoto T; Tse HF; Watson D; Weaver WD; Weiss R; Viigimaa M; Vinereanu D; Zhu J; Cannon CP; Wallentin L
    N Engl J Med; 2014 May; 370(18):1702-11. PubMed ID: 24678955
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effect of darapladib on plasma lipoprotein-associated phospholipase A2 activity in Japanese dyslipidemic patients, with exploratory analysis of a PLA2G7 gene polymorphism of Val279Phe.
    Daida H; Iwase T; Yagi S; Ando H; Nakajima H
    Circ J; 2013; 77(6):1518-25. PubMed ID: 23439604
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Chronic inhibition of lipoprotein-associated phospholipase A
    Prasad M; Lennon R; Barsness GW; Prasad A; Gulati R; Lerman LO; Lerman A
    Int J Cardiol; 2018 Feb; 253():7-13. PubMed ID: 29306475
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pharmacogenetic meta-analysis of baseline risk factors, pharmacodynamic, efficacy and tolerability endpoints from two large global cardiovascular outcomes trials for darapladib.
    Yeo A; Li L; Warren L; Aponte J; Fraser D; King K; Johansson K; Barnes A; MacPhee C; Davies R; Chissoe S; Tarka E; O'Donoghue ML; White HD; Wallentin L; Waterworth D
    PLoS One; 2017; 12(7):e0182115. PubMed ID: 28753643
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Darapladib, a Lipoprotein-Associated Phospholipase A2 Inhibitor, Reduces Rho Kinase Activity in Atherosclerosis.
    Zhang J; Xu DL; Liu XB; Bi SJ; Zhao T; Sui SJ; Ji XP; Lu QH
    Yonsei Med J; 2016 Mar; 57(2):321-7. PubMed ID: 26847282
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Genetic invalidation of Lp-PLA
    Gregson JM; Freitag DF; Surendran P; Stitziel NO; Chowdhury R; Burgess S; Kaptoge S; Gao P; Staley JR; Willeit P; Nielsen SF; Caslake M; Trompet S; Polfus LM; Kuulasmaa K; Kontto J; Perola M; Blankenberg S; Veronesi G; Gianfagna F; Männistö S; Kimura A; Lin H; Reilly DF; Gorski M; Mijatovic V; ; Munroe PB; Ehret GB; ; Thompson A; Uria-Nickelsen M; Malarstig A; Dehghan A; ; Vogt TF; Sasaoka T; Takeuchi F; Kato N; Yamada Y; Kee F; Müller-Nurasyid M; Ferrières J; Arveiler D; Amouyel P; Salomaa V; Boerwinkle E; Thompson SG; Ford I; Wouter Jukema J; Sattar N; Packard CJ; Shafi Majumder AA; Alam DS; Deloukas P; Schunkert H; Samani NJ; Kathiresan S; ; Nordestgaard BG; Saleheen D; Howson JM; Di Angelantonio E; Butterworth AS; Danesh J;
    Eur J Prev Cardiol; 2017 Mar; 24(5):492-504. PubMed ID: 27940953
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Lipoprotein-associated phospholipase A2 and its association with cardiovascular outcomes in patients with acute coronary syndromes in the PROVE IT-TIMI 22 (PRavastatin Or atorVastatin Evaluation and Infection Therapy-Thrombolysis In Myocardial Infarction) trial.
    O'Donoghue M; Morrow DA; Sabatine MS; Murphy SA; McCabe CH; Cannon CP; Braunwald E
    Circulation; 2006 Apr; 113(14):1745-52. PubMed ID: 16537575
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The effect of darapladib on plasma lipoprotein-associated phospholipase A2 activity and cardiovascular biomarkers in patients with stable coronary heart disease or coronary heart disease risk equivalent: the results of a multicenter, randomized, double-blind, placebo-controlled study.
    Mohler ER; Ballantyne CM; Davidson MH; Hanefeld M; Ruilope LM; Johnson JL; Zalewski A;
    J Am Coll Cardiol; 2008 Apr; 51(17):1632-41. PubMed ID: 18436114
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effect of darapladib on major coronary events after an acute coronary syndrome: the SOLID-TIMI 52 randomized clinical trial.
    O'Donoghue ML; Braunwald E; White HD; Lukas MA; Tarka E; Steg PG; Hochman JS; Bode C; Maggioni AP; Im K; Shannon JB; Davies RY; Murphy SA; Crugnale SE; Wiviott SD; Bonaca MP; Watson DF; Weaver WD; Serruys PW; Cannon CP; ; Steen DL
    JAMA; 2014 Sep; 312(10):1006-15. PubMed ID: 25173516
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Single and Multiple Dose Pharmacokinetics, Pharmacodynamics and Safety of the Novel Lipoprotein-Associated Phospholipase A2 Enzyme Inhibitor Darapladib in Healthy Chinese Subjects: An Open Label Phase-1 Clinical Trial.
    Hu C; Tompson D; Magee M; Chen Q; Liu YM; Zhu W; Zhao H; Gross AS; Liu Y
    PLoS One; 2015; 10(10):e0139862. PubMed ID: 26465780
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Inflammatory Biomarkers Interleukin-6 and C-Reactive Protein and Outcomes in Stable Coronary Heart Disease: Experiences From the STABILITY (Stabilization of Atherosclerotic Plaque by Initiation of Darapladib Therapy) Trial.
    Held C; White HD; Stewart RAH; Budaj A; Cannon CP; Hochman JS; Koenig W; Siegbahn A; Steg PG; Soffer J; Weaver WD; Östlund O; Wallentin L;
    J Am Heart Assoc; 2017 Oct; 6(10):. PubMed ID: 29066452
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Lipoprotein-associated Phospholipase A2 and Coronary Heart Disease.
    Sofogianni A; Alkagiet S; Tziomalos K
    Curr Pharm Des; 2018; 24(3):291-296. PubMed ID: 29332572
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Lipoprotein-associated phospholipase A2 in coronary heart disease: Review and meta-analysis.
    Li D; Zhao L; Yu J; Zhang W; Du R; Liu X; Liu Y; Chen Y; Zeng R; Cao Y; Zeng Z; Zhao Z; Wu J
    Clin Chim Acta; 2017 Feb; 465():22-29. PubMed ID: 27956130
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Diabetes status modifies the long-term effect of lipoprotein-associated phospholipase A2 on major coronary events.
    Siddiqui MK; Smith G; St Jean P; Dawed AY; Bell S; Soto-Pedre E; Kennedy G; Carr F; Wallentin L; White H; Macphee CH; Waterworth D; Palmer CNA
    Diabetologia; 2022 Jan; 65(1):101-112. PubMed ID: 34562103
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prognostic utility of lipoprotein-associated phospholipase A2 for cardiovascular outcomes in patients with stable coronary artery disease.
    Sabatine MS; Morrow DA; O'Donoghue M; Jablonksi KA; Rice MM; Solomon S; Rosenberg Y; Domanski MJ; Hsia J;
    Arterioscler Thromb Vasc Biol; 2007 Nov; 27(11):2463-9. PubMed ID: 17766330
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Study design and rationale for the clinical outcomes of the STABILITY Trial (STabilization of Atherosclerotic plaque By Initiation of darapLadIb TherapY) comparing darapladib versus placebo in patients with coronary heart disease.
    White H; Held C; Stewart R; Watson D; Harrington R; Budaj A; Steg PG; Cannon CP; Krug-Gourley S; Wittes J; Trivedi T; Tarka E; Wallentin L
    Am Heart J; 2010 Oct; 160(4):655-61. PubMed ID: 20934559
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Changes in lipoprotein-Associated phospholipase A2 activity predict coronary events and partly account for the treatment effect of pravastatin: results from the Long-Term Intervention with Pravastatin in Ischemic Disease study.
    White HD; Simes J; Stewart RA; Blankenberg S; Barnes EH; Marschner IC; Thompson P; West M; Zeller T; Colquhoun DM; Nestel P; Keech AC; Sullivan DR; Hunt D; Tonkin A;
    J Am Heart Assoc; 2013 Oct; 2(5):e000360. PubMed ID: 24152981
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Lipoprotein-associated phospholipase A2 and risk of incident cardiovascular disease in a multi-ethnic cohort: The multi ethnic study of atherosclerosis.
    Garg PK; McClelland RL; Jenny NS; Criqui MH; Greenland P; Rosenson RS; Siscovick DS; Jorgensen N; Cushman M
    Atherosclerosis; 2015 Jul; 241(1):176-82. PubMed ID: 26004387
    [TBL] [Abstract][Full Text] [Related]  

  • 20. PLA2G7 genotype, lipoprotein-associated phospholipase A2 activity, and coronary heart disease risk in 10 494 cases and 15 624 controls of European Ancestry.
    Casas JP; Ninio E; Panayiotou A; Palmen J; Cooper JA; Ricketts SL; Sofat R; Nicolaides AN; Corsetti JP; Fowkes FG; Tzoulaki I; Kumari M; Brunner EJ; Kivimaki M; Marmot MG; Hoffmann MM; Winkler K; März W; Ye S; Stirnadel HA; Boekholdt SM; Khaw KT; Humphries SE; Sandhu MS; Hingorani AD; Talmud PJ
    Circulation; 2010 Jun; 121(21):2284-93. PubMed ID: 20479152
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.